Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming

At a glance

Company: LIXTE Biotechnology Holdings Inc.
Ticker: NASDAQ: LIXT
Announcement: Acquisition

Key figures

Five-year overall survival with proton therapy: 90.9%
Five-year overall survival with traditional radiation: 81%
Patients enrolled in the trial: 440
U.S. proton centers in the trial: 21

Products and programs

LiGHT proton therapy platform

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation
Proton therapy’s ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary of LIXTE and developer of the electronically controlled LiGHT proton therapy platform

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core limitation persisted: photon beams pass through the body, leaving an exit dose of radiation in tissue beyond the tumor. The question oncologists repeatedly returned to was not whether this collateral exposure mattered, but how much it mattered over a patient’s lifetime. A landmark study published in The Lancet in December 2025 offered some of the clearest evidence yet, and the findings are beginning to influence how cancer treatment infrastructure is being planned.

A Survival Gap That Changes Conversation

The University of Texas MD Anderson Cancer Center led the largest randomized Phase III trial to date comparing proton therapy to traditional radiation therapy in patients with oropharyngeal cancer. The study enrolled 440 patients across 21 proton centers in the U.S. and tracked outcomes over…

In brief

The release highlights findings from a randomized Phase III comparison of proton and conventional radiation for oropharyngeal cancer. It reports five-year overall survival of 90.9% among proton therapy patients, versus 81% among patients receiving traditional radiation. The study, led by MD Anderson Cancer Center, enrolled 440 patients at 21 U.S. proton centers, according to the release. It also describes proton therapy’s ability to limit radiation beyond a tumor and notes growing investment in treatment facilities, including a center planned for Boca Raton, Florida. LIXTE Biotechnology Holdings acquired Liora Technologies Europe in November 2025; Liora, now a LIXTE subsidiary, develops the electronically controlled LiGHT proton therapy platform.

Key takeaways

The release reports five-year overall survival rates of 90.9% with proton therapy and 81% with traditional radiation.
MD Anderson led the Phase III trial, which enrolled 440 patients at 21 U.S. proton centers.
LIXTE acquired Liora Technologies Europe in November 2025; Liora develops the LiGHT proton therapy platform.
A proton therapy center in Boca Raton is scheduled to open this summer, according to the release.

Earlier from LIXTE Biotechnology Holdings Inc.

Back to News Center